289 related articles for article (PubMed ID: 25082556)
61. Effects of abaloparatide, a human parathyroid hormone-related peptide analog, on bone mineral density in postmenopausal women with osteoporosis.
Leder BZ; O'Dea LS; Zanchetta JR; Kumar P; Banks K; McKay K; Lyttle CR; Hattersley G
J Clin Endocrinol Metab; 2015 Feb; 100(2):697-706. PubMed ID: 25393645
[TBL] [Abstract][Full Text] [Related]
62. Overlapping and continued alendronate or raloxifene administration in patients on teriparatide: effects on areal and volumetric bone mineral density--the CONFORS Study.
Muschitz C; Kocijan R; Fahrleitner-Pammer A; Pavo I; Haschka J; Schima W; Kapiotis S; Resch H
J Bone Miner Res; 2014 Aug; 29(8):1777-85. PubMed ID: 24619763
[TBL] [Abstract][Full Text] [Related]
63. Effects of teriparatide treatment and discontinuation in postmenopausal women and eugonadal men with osteoporosis.
Leder BZ; Neer RM; Wyland JJ; Lee HW; Burnett-Bowie SM; Finkelstein JS
J Clin Endocrinol Metab; 2009 Aug; 94(8):2915-21. PubMed ID: 19435827
[TBL] [Abstract][Full Text] [Related]
64. A retrospective analysis of nonresponse to daily teriparatide treatment.
Niimi R; Kono T; Nishihara A; Hasegawa M; Kono T; Sudo A
Osteoporos Int; 2016 Sep; 27(9):2845-2853. PubMed ID: 27055464
[TBL] [Abstract][Full Text] [Related]
65. Analyzing the factors associated with efficacy among teriparatide treatment in postmenopausal women with osteoporosis.
Kong M; Gao C; Luan X; Fan C; Hao M; Jin C; Zhao J; Li H; Zhao J; Luan J; Lin Y; Li Q
BMC Musculoskelet Disord; 2024 Feb; 25(1):109. PubMed ID: 38310278
[TBL] [Abstract][Full Text] [Related]
66. The effects of ronacaleret, a calcium-sensing receptor antagonist, on bone mineral density and biochemical markers of bone turnover in postmenopausal women with low bone mineral density.
Fitzpatrick LA; Dabrowski CE; Cicconetti G; Gordon DN; Papapoulos S; Bone HG; Bilezikian JP
J Clin Endocrinol Metab; 2011 Aug; 96(8):2441-9. PubMed ID: 21593114
[TBL] [Abstract][Full Text] [Related]
67. Improved adherence with PTH(1-84) in an extension trial for 24 months results in enhanced BMD gains in the treatment of postmenopausal women with osteoporosis.
Black DM; Bilezikian JP; Greenspan SL; Wüster C; Muñoz-Torres M; Bone HG; Rosen CJ; Andersen HS; Hanley DA
Osteoporos Int; 2013 Apr; 24(4):1503-11. PubMed ID: 22930240
[TBL] [Abstract][Full Text] [Related]
68. An investigation of the differential therapeutic effects of romosozumab on postmenopausal osteoporosis patients with or without rheumatoid arthritis complications: a case-control study.
Ebina K; Nagayama Y; Kashii M; Tsuboi H; Okamura G; Miyama A; Etani Y; Noguchi T; Hirao M; Miura T; Fukuda Y; Kurihara T; Nakata K; Okada S
Osteoporos Int; 2024 May; 35(5):841-849. PubMed ID: 38296866
[TBL] [Abstract][Full Text] [Related]
69. Effect of strontium ranelate on lumbar spine bone mineral density in women with established osteoporosis previously treated with teriparatide.
Anastasilakis AD; Polyzos SA; Avramidis A; Papatheodorou A; Terpos E
Horm Metab Res; 2009 Jul; 41(7):559-62. PubMed ID: 19204890
[TBL] [Abstract][Full Text] [Related]
70. Longitudinal changes in bone mineral density and trabecular bone score following yearly zoledronic acid infusion in postmenopausal osteoporosis-a retrospective-prospective study from southern India.
Sooragonda B; Cherian KE; Jebasingh FK; Dasgupta R; Asha HS; Kapoor N; Thomas N; Paul TV
Arch Osteoporos; 2019 Jul; 14(1):79. PubMed ID: 31321603
[TBL] [Abstract][Full Text] [Related]
71. Skeletal response to treatment with teriparatide (TPD) after bisphosphonate in post-menopausal women with osteoporosis and a high prevalence of secondary risk factors in real-life setting of a metabolic bone clinic; effect of age and vitamin D status.
Mok J; Brown C; Moore AEB; Min SS; Hampson G
Endocr Res; 2018 Aug; 43(3):195-202. PubMed ID: 29652557
[TBL] [Abstract][Full Text] [Related]
72. The effect of prior bisphosphonate exposure on the treatment response to teriparatide in clinical practice.
Middleton ET; Steel SA; Doherty SM
Calcif Tissue Int; 2007 Nov; 81(5):335-40. PubMed ID: 17938845
[TBL] [Abstract][Full Text] [Related]
73. Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status.
Langdahl BL; Marin F; Shane E; Dobnig H; Zanchetta JR; Maricic M; Krohn K; See K; Warner MR
Osteoporos Int; 2009 Dec; 20(12):2095-104. PubMed ID: 19350340
[TBL] [Abstract][Full Text] [Related]
74. Variability in the measured response of bone to teriparatide.
Heaney RP; Watson P
Osteoporos Int; 2011 Jun; 22(6):1703-8. PubMed ID: 20827548
[TBL] [Abstract][Full Text] [Related]
75. Determinants associated with bone mineral density increase in response to daily teriparatide treatment in patients with osteoporosis.
Niimi R; Kono T; Nishihara A; Hasegawa M; Matsumine A; Kono T; Sudo A
Bone; 2014 Sep; 66():26-30. PubMed ID: 24909538
[TBL] [Abstract][Full Text] [Related]
76. Are changes in bone mineral density different between groups of early rheumatoid arthritis patients treated according to a tight control strategy with or without prednisone if osteoporosis prophylaxis is applied?
van der Goes MC; Jacobs JW; Jurgens MS; Bakker MF; van der Veen MJ; van der Werf JH; Welsing PM; Bijlsma JW
Osteoporos Int; 2013 Apr; 24(4):1429-36. PubMed ID: 23011680
[TBL] [Abstract][Full Text] [Related]
77. Effects of follow-on therapy after denosumab discontinuation in patients with postmenopausal osteoporosis.
Ebina K; Hashimoto J; Kashii M; Hirao M; Miyama A; Nakaya H; Tsuji S; Takahi K; Tsuboi H; Okamura G; Etani Y; Takami K; Yoshikawa H
Mod Rheumatol; 2021 Mar; 31(2):485-492. PubMed ID: 32412351
[TBL] [Abstract][Full Text] [Related]
78. Relationship between P1NP, a biochemical marker of bone turnover, and bone mineral density in patients transitioned from alendronate to romosozumab or teriparatide: a post hoc analysis of the STRUCTURE trial.
Takada J; Dinavahi R; Miyauchi A; Hamaya E; Hirama T; Libanati C; Nakamura Y; Milmont CE; Grauer A
J Bone Miner Metab; 2020 May; 38(3):310-315. PubMed ID: 31707465
[TBL] [Abstract][Full Text] [Related]
79. Single and combined use of human parathyroid hormone (PTH) (1-34) on areal bone mineral density (aBMD) in postmenopausal women with osteoporosis: evidence based on 9 RCTs.
Song J; Jin Z; Chang F; Li L; Su Y
Med Sci Monit; 2014 Dec; 20():2624-32. PubMed ID: 25503108
[TBL] [Abstract][Full Text] [Related]
80. Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis.
Boonen S; Marin F; Obermayer-Pietsch B; Simões ME; Barker C; Glass EV; Hadji P; Lyritis G; Oertel H; Nickelsen T; McCloskey EV;
J Clin Endocrinol Metab; 2008 Mar; 93(3):852-60. PubMed ID: 18160462
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
